Kesimpta (Ofatumumab)

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Prescription Required

  • Product Details

    Description

    Kesimpta (ofatumumab) is a prescription medication for treating relapsing forms of multiple sclerosis (MS). It is a monoclonal antibody that targets and binds to a specific protein found on the surface of B-cells, a type of immune cell involved in the development of MS.

    Kesimpta is available in a prefilled syringe and is administered as a subcutaneous injection.


    Fact Table

    Formula

    C6480H10022N1742O2020S44

    License

    US FDA, EU EMA

    Bioavailability

    70%

    Legal status

    Rx-Only

    Chemical Name

    Ofatumumab

    Elimination half-life

    14 days

    Dosage (Strength)

    -

    Pregnancy

    Consult Doctor

    Brands

    kesimpta

    Protein binding

    Limited information

    PubChem CID

    Not Available

    MedlinePlus

    a621050

    ChEBI

    Not Available

    ATC code

    L01FA02

    DrugBank

    DB06650

    KEGG

    D09314

    Routes of administration

    Subcutaneous

    Directions

    The first dose is administered alongside a healthcare professional. Your healthcare provider will provide you with a schedule for subsequent injections.

    Ingredients

    The active ingredient in Kesimpta is ofatumumab.

    Interactions

    Common drug-drug interactions may include:

    • Abrocitinib
    • Baricitinib
    • BCG Products
    • Cladribine
    • Coccidioides immitis Skin Test
    • COVID-19 Vaccines
    • Dengue Tetravalent Vaccine
    • Denosumab
    • Deucravacitinib
    • Filgotinib
    • Influenza Virus Vaccines
    • Leflunomide
    • Mumps- Rubella- or Varicella-Containing Live Vaccines
    • Nadofaragene Firadenovec
    • Natalizumab
    • Ocrelizumab
    • Pimecrolimus
    • Poliovirus Vaccine
    • Polymethylmethacrylate
    • Rabies Vaccine
    • Ruxolitinib
    • Sipuleucel-T
    • Tacrolimus
    • Talimogene Laherparepvec
    • Tertomotide
    • Tofacitinib
    • Typhoid Vaccine
    • Upadacitinib
    • Vaccines (Inactivated/Non-Replicating)
    • Vaccines (Live)
    • Yellow Fever Vaccine

    Cautions

    Do not take Kesimpta if you are allergic to ofatumumab or any other ingredient in the medication.

    Before starting Kesimpta, inform your healthcare provider if you have a history of hepatitis B infection, as the medication may reactivate the virus.

    It is important to monitor for signs of infection while using Kesimpta, as it may increase the risk of infection.

    Side Effects

    The most common side effects of Kesimpta may include:

    • Anemia
    • Back pain
    • Bronchitis
    • Chills
    • Cough
    • Decreased serum immunoglobulins
    • Diarrhea
    • Dyspnea
    • Fatigue
    • Fever
    • Headache
    • Hepatitis B
    • Herpes zoster infection
    • Hyperhidrosis
    • Hypertension
    • Hypogammaglobulinemia
    • Hypotension
    • Infection
    • Influenza
    • Infusion-related reaction
    • Injection site reaction
    • Insomnia
    • Muscle spasm
    • Nasopharyngitis
    • Neutropenia
    • Peripheral edema
    • Pneumonia
    • Porphyria cutanea tarda
    • Progressive multifocal leukoencephalopathy
    • Sepsis
    • Serious Infection
    • Sinusitis
    • Skin rash
    • Stevens-Johnson syndrome
    • Tachycardia
    • Tumor lysis syndrome
    • Upper respiratory tract infection
    • Urinary tract infection
    • Urticaria

    References

    Kesimpta [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.


    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 13855

  • Product Reviews

Processing..

Please wait while the page is loading. Do not hit refresh or the browser back button to avoid any loss of information.

If you have any questions or concerns, please contact our Customer Service team via the chat option on our website or calling us toll free at: 1-800-891-0844